The FDA’s final SIUU guidance, published in January 2025, marks a pivotal shift in how drug and device manufacturers share scientific information about unapproved uses with healthcare providers (HCPs). For the first time, the framework explicitly permits sales and marketing personnel to share off-label scientific data during detailing visits. It also allows firms to post such content on their websites. Furthermore, it expands the types of evidence that qualify under the safe harbor. However, implementing these permissions compliantly and at scale remains a significant challenge. Companies that treat this guidance as a green light — without careful preparation — risk enforcement action.
What the FDA SIUU Guidance Changes
The final guidance, formally titled Communications From Firms to Health Care Providers Regarding Scientific Information on Unapproved Uses of Approved/Cleared Medical Products, resolves regulatory uncertainty that has persisted for nearly three decades. Three headline changes stand out.
Sales Personnel Can Now Share Off-Label Data
Previously, sharing off-label scientific information was largely confined to Medical Affairs teams. Now, sales and marketing personnel may share such content — provided they receive specialized training and maintain meaningful separation between off-label sharing and on-label promotion.
Website Publication Is Explicitly Permitted
Firms may publish SIUU content on their websites. Additionally, the FDA recommends placing this content on a separate web page, away from any promotional material. Content selection must not create a misleading impression of the product or unapproved use.
Expanded Evidence Types Qualify
The word “clinically relevant” — previously criticized as vague and restrictive — no longer defines eligible source publications. Consequently, certain early-stage clinical data and other study types may now qualify as “scientifically sound,” opening the door to sharing information from more stages of product development.
The Core Regulatory Tension
Under the Federal Food, Drug, and Cosmetic Act, manufacturers generally cannot promote products for uses the FDA has not approved. Yet physicians routinely prescribe approved products off-label, especially when no approved alternatives exist. This creates a persistent conflict: HCPs need data to make sound clinical decisions, but manufacturers risk blurring the line between scientific exchange and promotion. The SIUU guidance attempts to resolve this tension by defining a narrow safe harbor for non-promotional scientific sharing.
Three Decades of Policy Evolution
The FDA has refined this framework across nearly 30 years. Congress first addressed off-label communication in 1997 through the Food and Drug Administration Modernization Act (FDAMA). That law created a safe harbor for sharing medical articles about unapproved uses — but those provisions expired in 2006.
Subsequently, First Amendment litigation complicated the FDA’s authority to restrict truthful off-label information. In response, the agency issued its “Good Reprints” guidance in 2009, then expanded it in 2014 to include clinical practice guidelines. A more substantial 2023 draft guidance allowed firm-generated presentations of scientific information and cautioned against persuasive marketing techniques. Finally, the 2025 final guidance built on all of this, offering the clearest — and most actionable — framework to date.
Key Practical Impacts for Manufacturers
Manufacturers who want to benefit from this policy must understand its specific requirements. Several areas demand close attention.
Required Disclosures Are Non-Negotiable
All required disclosures must appear “clearly and prominently” in every SIUU communication. This means careful attention to font size, graphic design, and audio parameters where applicable. Brand teams accustomed to traditional marketing materials may find the volume of required caveats uncomfortable. Nevertheless, these disclosures are mandatory.
Platform Selection Is a Compliance Factor
A communication that otherwise satisfies the guidance becomes non-compliant if the delivery channel cannot accommodate all required disclosures. Character-limited media, for instance, do not meet this standard. Therefore, firms must evaluate platform suitability before distributing SIUU materials.
Certain Communication Methods Are Prohibited
Celebrity endorsements, emotional appeals unrelated to scientific content, promotional taglines, jingles, gifts, premium offers, and certain calls to value all fall outside the safe harbor. Moreover, any content that pairs a call to action with a value proposition — such as “Click here to learn more and save” — exceeds permissible bounds.
Enforcement Signals Worth Watching
No companies have faced public citations specifically for violating the 2025 guidance. However, enforcement signals are already visible. The FDA’s elevated enforcement activity in late 2025 and early 2026 shows regulators acting against off-label communications that fall outside the safe harbor.
A Warning Letter That Sets the Tone
One September 2025 Warning Letter is especially instructive. The FDA cited a firm for promoting laser devices as treating conditions not addressed by standard medical care. The agency highlighted a case study that attributed the cure of a patient’s peripheral neuropathy to the company’s device. Critically, the FDA does not consider a singular, undocumented case study to constitute “scientifically sound” evidence. Thus, the letter signals how regulators interpret the new standard in practice.
How Companies Should Respond Now
Companies wishing to benefit from the final SIUU policy should take two immediate steps. First, ensure the guidance’s criteria are consistently embedded in existing compliance infrastructure. Second, conduct a gap analysis of all current SIUU-like communications against the guidance’s specific requirements.
Beyond that, firms involving non-Medical Affairs personnel in in-person SIUU distribution must develop robust training programs. Detailed documentation of training content and attendees will be essential in any future enforcement review.
The 2025 SIUU guidance is more restrictive than many manufacturers would prefer. Still, it is also the clearest framework the industry has ever had. Manufacturers who invest the effort to understand its boundaries can operationalize it effectively — for both their business and patient care. Those who proceed without that investment should not expect the safe harbor to protect them.
